Essential Partners
CRBP icon

Essential Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Essential Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$239 Buy
+35
New +$323 ﹤0.01% 2559
2025
Q4 		– Sell
-56
Closed -$708 – 2804
2025
Q3 		$708 Sell
56
-53
-49% -$504 ﹤0.01% 2117
2025
Q2 		$752 Buy
+109
New +$792 ﹤0.01% 1582

Other funds holding CRBP

Doliver Advisors
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Essential Partners's CRBP Position: Q3 2026 in Review

Essential Partners opened a new position in Corbus Pharmaceuticals (CRBP) in Q3 2026: 35 shares worth $239. The stake represents ﹤0.01% of the portfolio and ranks #2559 among its holdings. This is a return to the name: Essential Partners previously reported a position in CRBP as recently as Q3 2025.

Essential Partners first reported a position in CRBP in Q2 2025 and has held it in 3 quarters since. The position peaked at $752 in Q2 2025. 14 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.

  • Essential Partners held 35 shares of Corbus Pharmaceuticals worth $239 as of Q3 2026.
  • Corbus Pharmaceuticals was a new Essential Partners position in Q3 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2559 holding.
  • Essential Partners first reported a position in Corbus Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Essential Partners's Corbus Pharmaceuticals position peaked at $752 in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.